Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Pharmaceuticals ETF

98.65
-0.3500-0.35%
Post-market: 98.650.00000.00%19:30 EDT
Volume:663.75K
Turnover:65.34M
Market Cap:1.60B
PE:9.19
High:99.48
Open:99.33
Low:98.25
Close:99.00
52wk High:108.66
52wk Low:72.94
Shares:16.25M
Float Shares:16.25M
Volume Ratio:4.65
T/O Rate:4.08%
Dividend:1.44
Dividend Rate:1.46%
EPS(TTM):10.74
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Novo Bets on Next Chapter While Eli Lilly Extends Its GLP-1 Dominance

Deep News
·
Sep 25

Johnson & Johnson says Tremfya met endpoints in Phase 4 STAR study

TIPRANKS
·
Sep 25

J&J - Star Study Shows Tremfya Safety Profile Consistent with Psa; no New Safety Signals

THOMSON REUTERS
·
Sep 25

J&J - Tremfya Meets Primary Endpoint for Basdai Score Improvement at Week 24

THOMSON REUTERS
·
Sep 25

J&J - Tremfya Meets Primary and Major Secondary Endpoints in Axial Psa Study

THOMSON REUTERS
·
Sep 25

Johnson & Johnson Announces Tremfya® (Guselkumab) is the First and Only Il-23 Inhibitor to Show Significant Improvement in Spinal Pain and Stiffness in Landmark Axial Psoriatic Arthritis (Psa) Study

THOMSON REUTERS
·
Sep 25

Single Infusion of Carvykti Delivered Five-Year Treatment-Free Remissions in 50% of Patients in Early Line Relapsed/Refractory Multiple Myeloma

Reuters
·
Sep 25

Nektar Therapeutics - Jury Finds Lilly Breached Implied Covenant of Good Faith in License Agreement - SEC Filing

THOMSON REUTERS
·
Sep 25

J&J - Carvykti Delivers Five-Year Treatment-Free Remissions in 50% of Early Line Rrmm Patients

THOMSON REUTERS
·
Sep 25

J&J - Five-Year Overall Survival Rate 69.2%, Median Progression-Free Survival 60.5 Months

THOMSON REUTERS
·
Sep 25

FDA Approves Merck’s Welireg Plus Eisai’s Lenvima for Previously Treated Advanced Clear Cell Kidney Cancer

Reuters
·
Sep 25

Surrozen price target raised to $54 from $44 at H.C. Wainwright

TIPRANKS
·
Sep 25

Bal Pharma Closes Trading Window Ahead of Q2 FY27 Results

TIPRANKS
·
Sep 25

Estee Lauder Cos. Cl a Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Sep 25

Nanobiotix advances cancer nanotherapeutics and bolsters cash runway into 2029

TIPRANKS
·
Sep 25

France's Nanobiotix H1 Net Loss Widens on Lower Revenue, Absence of 2025 One-Off Gain

Reuters
·
Sep 25

Press Release: Nanobiotix Provides First Half 2026 Operational and Financial Update

Dow Jones
·
Sep 25

Royalty Pharma EVP Christopher Hite Disposes of 100,000 Common Shares Worth $5,853,719.88

Reuters
·
Sep 25

FDA approves Welireg and Lenvima combo for ccRCC

TIPRANKS
·
Sep 25

Merck Shares Flat in Volume Spike After FDA Approves Kidney Drug, Last up 0.50% at $148.81

THOMSON REUTERS
·
Sep 25